nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Methotrexate—esophageal cancer	0.732	1	CbGbCtD
Brimonidine—Rosacea—Capecitabine—esophageal cancer	0.00667	0.0497	CcSEcCtD
Brimonidine—Punctate keratitis—Capecitabine—esophageal cancer	0.00576	0.043	CcSEcCtD
Brimonidine—Scab—Capecitabine—esophageal cancer	0.00458	0.0341	CcSEcCtD
Brimonidine—Blindness—Cisplatin—esophageal cancer	0.00357	0.0266	CcSEcCtD
Brimonidine—Peripheral coldness—Capecitabine—esophageal cancer	0.00306	0.0228	CcSEcCtD
Brimonidine—Infection—Carboplatin—esophageal cancer	0.00239	0.0178	CcSEcCtD
Brimonidine—Keratitis—Capecitabine—esophageal cancer	0.00224	0.0167	CcSEcCtD
Brimonidine—Pain—Carboplatin—esophageal cancer	0.00205	0.0153	CcSEcCtD
Brimonidine—Osteoporosis—Methotrexate—esophageal cancer	0.00193	0.0144	CcSEcCtD
Brimonidine—Hypoxia—Methotrexate—esophageal cancer	0.00171	0.0127	CcSEcCtD
Brimonidine—Eye irritation—Capecitabine—esophageal cancer	0.0017	0.0127	CcSEcCtD
Brimonidine—Lacrimation increased—Capecitabine—esophageal cancer	0.00158	0.0118	CcSEcCtD
Brimonidine—Nasal congestion—Cisplatin—esophageal cancer	0.00157	0.0117	CcSEcCtD
Brimonidine—Burning sensation—Methotrexate—esophageal cancer	0.00156	0.0116	CcSEcCtD
Brimonidine—Cyanosis—Methotrexate—esophageal cancer	0.00153	0.0114	CcSEcCtD
Brimonidine—Cataract—Capecitabine—esophageal cancer	0.00153	0.0114	CcSEcCtD
Brimonidine—Face oedema—Cisplatin—esophageal cancer	0.00138	0.0103	CcSEcCtD
Brimonidine—Dry eye—Capecitabine—esophageal cancer	0.00134	0.01	CcSEcCtD
Brimonidine—Nasopharyngitis—Cisplatin—esophageal cancer	0.00128	0.00956	CcSEcCtD
Brimonidine—Apnoea—Methotrexate—esophageal cancer	0.00128	0.00953	CcSEcCtD
Brimonidine—Abnormal vision—Capecitabine—esophageal cancer	0.00127	0.00947	CcSEcCtD
Brimonidine—Diabetes mellitus—Capecitabine—esophageal cancer	0.00121	0.00906	CcSEcCtD
Brimonidine—Swelling—Capecitabine—esophageal cancer	0.0012	0.00893	CcSEcCtD
Brimonidine—Eye pain—Capecitabine—esophageal cancer	0.00117	0.00873	CcSEcCtD
Brimonidine—Respiratory failure—Methotrexate—esophageal cancer	0.0011	0.00823	CcSEcCtD
Brimonidine—Arthritis—Capecitabine—esophageal cancer	0.00109	0.00811	CcSEcCtD
Brimonidine—Lethargy—Capecitabine—esophageal cancer	0.00108	0.00804	CcSEcCtD
Brimonidine—Conjunctivitis—Cisplatin—esophageal cancer	0.00107	0.00801	CcSEcCtD
Brimonidine—Osteoarthritis—Capecitabine—esophageal cancer	0.00106	0.00788	CcSEcCtD
Brimonidine—Face oedema—Capecitabine—esophageal cancer	0.00102	0.00761	CcSEcCtD
Brimonidine—Bradycardia—Cisplatin—esophageal cancer	0.00101	0.00753	CcSEcCtD
Brimonidine—Coma—Methotrexate—esophageal cancer	0.00099	0.00739	CcSEcCtD
Brimonidine—Dry skin—Capecitabine—esophageal cancer	0.000969	0.00722	CcSEcCtD
Brimonidine—Visual impairment—Cisplatin—esophageal cancer	0.000956	0.00713	CcSEcCtD
Brimonidine—Nasopharyngitis—Capecitabine—esophageal cancer	0.000945	0.00705	CcSEcCtD
Brimonidine—Eye disorder—Cisplatin—esophageal cancer	0.000927	0.00691	CcSEcCtD
Brimonidine—Flushing—Cisplatin—esophageal cancer	0.00092	0.00686	CcSEcCtD
Brimonidine—Cardiac disorder—Cisplatin—esophageal cancer	0.00092	0.00686	CcSEcCtD
Brimonidine—Influenza—Capecitabine—esophageal cancer	0.000913	0.00681	CcSEcCtD
Brimonidine—Diabetes mellitus—Methotrexate—esophageal cancer	0.000904	0.00675	CcSEcCtD
Brimonidine—Immune system disorder—Cisplatin—esophageal cancer	0.000896	0.00668	CcSEcCtD
Brimonidine—Mediastinal disorder—Cisplatin—esophageal cancer	0.000894	0.00667	CcSEcCtD
Brimonidine—Arrhythmia—Cisplatin—esophageal cancer	0.000886	0.00661	CcSEcCtD
Brimonidine—Bronchitis—Capecitabine—esophageal cancer	0.000878	0.00655	CcSEcCtD
Brimonidine—Erythema—Cisplatin—esophageal cancer	0.000863	0.00644	CcSEcCtD
Brimonidine—Visual disturbance—Methotrexate—esophageal cancer	0.00083	0.00619	CcSEcCtD
Brimonidine—Vision blurred—Cisplatin—esophageal cancer	0.000814	0.00607	CcSEcCtD
Brimonidine—Depression—Capecitabine—esophageal cancer	0.000812	0.00606	CcSEcCtD
Brimonidine—Lethargy—Methotrexate—esophageal cancer	0.000803	0.00599	CcSEcCtD
Brimonidine—Conjunctivitis—Capecitabine—esophageal cancer	0.000792	0.0059	CcSEcCtD
Brimonidine—Osteoarthritis—Methotrexate—esophageal cancer	0.000787	0.00587	CcSEcCtD
Brimonidine—Bradycardia—Capecitabine—esophageal cancer	0.000744	0.00555	CcSEcCtD
Brimonidine—Myalgia—Cisplatin—esophageal cancer	0.000735	0.00548	CcSEcCtD
Brimonidine—Rhinitis—Capecitabine—esophageal cancer	0.000733	0.00547	CcSEcCtD
Brimonidine—Anxiety—Cisplatin—esophageal cancer	0.000732	0.00546	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00073	0.00544	CcSEcCtD
Brimonidine—Discomfort—Cisplatin—esophageal cancer	0.000726	0.00542	CcSEcCtD
Brimonidine—Pharyngitis—Capecitabine—esophageal cancer	0.000726	0.00541	CcSEcCtD
Brimonidine—Oedema—Cisplatin—esophageal cancer	0.000705	0.00525	CcSEcCtD
Brimonidine—Visual impairment—Capecitabine—esophageal cancer	0.000704	0.00525	CcSEcCtD
Brimonidine—Infection—Cisplatin—esophageal cancer	0.0007	0.00522	CcSEcCtD
Brimonidine—Nervous system disorder—Cisplatin—esophageal cancer	0.000691	0.00515	CcSEcCtD
Brimonidine—Tachycardia—Cisplatin—esophageal cancer	0.000688	0.00513	CcSEcCtD
Brimonidine—Skin disorder—Cisplatin—esophageal cancer	0.000684	0.0051	CcSEcCtD
Brimonidine—Eye disorder—Capecitabine—esophageal cancer	0.000683	0.0051	CcSEcCtD
Brimonidine—Flushing—Capecitabine—esophageal cancer	0.000678	0.00506	CcSEcCtD
Brimonidine—Cardiac disorder—Capecitabine—esophageal cancer	0.000678	0.00506	CcSEcCtD
Brimonidine—Angiopathy—Capecitabine—esophageal cancer	0.000663	0.00495	CcSEcCtD
Brimonidine—Immune system disorder—Capecitabine—esophageal cancer	0.00066	0.00492	CcSEcCtD
Brimonidine—Mediastinal disorder—Capecitabine—esophageal cancer	0.000659	0.00491	CcSEcCtD
Brimonidine—Hypotension—Cisplatin—esophageal cancer	0.000658	0.00491	CcSEcCtD
Brimonidine—Arrhythmia—Capecitabine—esophageal cancer	0.000653	0.00487	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000642	0.00479	CcSEcCtD
Brimonidine—Mental disorder—Capecitabine—esophageal cancer	0.00064	0.00478	CcSEcCtD
Brimonidine—Erythema—Capecitabine—esophageal cancer	0.000636	0.00475	CcSEcCtD
Brimonidine—Paraesthesia—Cisplatin—esophageal cancer	0.000633	0.00472	CcSEcCtD
Brimonidine—Dyspnoea—Cisplatin—esophageal cancer	0.000628	0.00468	CcSEcCtD
Brimonidine—Dysgeusia—Capecitabine—esophageal cancer	0.000623	0.00465	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000608	0.00454	CcSEcCtD
Brimonidine—Drowsiness—Methotrexate—esophageal cancer	0.000606	0.00452	CcSEcCtD
Brimonidine—Depression—Methotrexate—esophageal cancer	0.000604	0.00451	CcSEcCtD
Brimonidine—Pain—Cisplatin—esophageal cancer	0.000603	0.00449	CcSEcCtD
Brimonidine—Vision blurred—Capecitabine—esophageal cancer	0.0006	0.00447	CcSEcCtD
Brimonidine—Conjunctivitis—Methotrexate—esophageal cancer	0.000589	0.00439	CcSEcCtD
Brimonidine—Syncope—Capecitabine—esophageal cancer	0.000571	0.00426	CcSEcCtD
Brimonidine—Palpitations—Capecitabine—esophageal cancer	0.000562	0.00419	CcSEcCtD
Brimonidine—Loss of consciousness—Capecitabine—esophageal cancer	0.000559	0.00417	CcSEcCtD
Brimonidine—Cough—Capecitabine—esophageal cancer	0.000555	0.00414	CcSEcCtD
Brimonidine—Hypertension—Capecitabine—esophageal cancer	0.000549	0.0041	CcSEcCtD
Brimonidine—Chest pain—Capecitabine—esophageal cancer	0.000542	0.00404	CcSEcCtD
Brimonidine—Myalgia—Capecitabine—esophageal cancer	0.000542	0.00404	CcSEcCtD
Brimonidine—Arthralgia—Capecitabine—esophageal cancer	0.000542	0.00404	CcSEcCtD
Brimonidine—Pharyngitis—Methotrexate—esophageal cancer	0.00054	0.00403	CcSEcCtD
Brimonidine—Anxiety—Capecitabine—esophageal cancer	0.00054	0.00403	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000538	0.00401	CcSEcCtD
Brimonidine—Discomfort—Capecitabine—esophageal cancer	0.000535	0.00399	CcSEcCtD
Brimonidine—Dry mouth—Capecitabine—esophageal cancer	0.00053	0.00395	CcSEcCtD
Brimonidine—Visual impairment—Methotrexate—esophageal cancer	0.000524	0.00391	CcSEcCtD
Brimonidine—Oedema—Capecitabine—esophageal cancer	0.000519	0.00387	CcSEcCtD
Brimonidine—Hypersensitivity—Cisplatin—esophageal cancer	0.000519	0.00387	CcSEcCtD
Brimonidine—Infection—Capecitabine—esophageal cancer	0.000516	0.00385	CcSEcCtD
Brimonidine—Shock—Capecitabine—esophageal cancer	0.000511	0.00381	CcSEcCtD
Brimonidine—Nervous system disorder—Capecitabine—esophageal cancer	0.000509	0.0038	CcSEcCtD
Brimonidine—Eye disorder—Methotrexate—esophageal cancer	0.000509	0.00379	CcSEcCtD
Brimonidine—Tachycardia—Capecitabine—esophageal cancer	0.000507	0.00378	CcSEcCtD
Brimonidine—Asthenia—Cisplatin—esophageal cancer	0.000506	0.00377	CcSEcCtD
Brimonidine—Cardiac disorder—Methotrexate—esophageal cancer	0.000505	0.00377	CcSEcCtD
Brimonidine—Skin disorder—Capecitabine—esophageal cancer	0.000504	0.00376	CcSEcCtD
Brimonidine—Angiopathy—Methotrexate—esophageal cancer	0.000494	0.00368	CcSEcCtD
Brimonidine—Immune system disorder—Methotrexate—esophageal cancer	0.000492	0.00367	CcSEcCtD
Brimonidine—Mediastinal disorder—Methotrexate—esophageal cancer	0.00049	0.00366	CcSEcCtD
Brimonidine—Hypotension—Capecitabine—esophageal cancer	0.000485	0.00362	CcSEcCtD
Brimonidine—Mental disorder—Methotrexate—esophageal cancer	0.000477	0.00356	CcSEcCtD
Brimonidine—Erythema—Methotrexate—esophageal cancer	0.000474	0.00353	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000473	0.00353	CcSEcCtD
Brimonidine—Insomnia—Capecitabine—esophageal cancer	0.00047	0.0035	CcSEcCtD
Brimonidine—Paraesthesia—Capecitabine—esophageal cancer	0.000466	0.00348	CcSEcCtD
Brimonidine—Dysgeusia—Methotrexate—esophageal cancer	0.000464	0.00346	CcSEcCtD
Brimonidine—Dyspnoea—Capecitabine—esophageal cancer	0.000463	0.00345	CcSEcCtD
Brimonidine—Dyspepsia—Capecitabine—esophageal cancer	0.000457	0.00341	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000448	0.00334	CcSEcCtD
Brimonidine—Fatigue—Capecitabine—esophageal cancer	0.000448	0.00334	CcSEcCtD
Brimonidine—Vision blurred—Methotrexate—esophageal cancer	0.000446	0.00333	CcSEcCtD
Brimonidine—Rash—Cisplatin—esophageal cancer	0.000444	0.00331	CcSEcCtD
Brimonidine—Pain—Capecitabine—esophageal cancer	0.000444	0.00331	CcSEcCtD
Brimonidine—Dermatitis—Cisplatin—esophageal cancer	0.000444	0.00331	CcSEcCtD
Brimonidine—Nausea—Cisplatin—esophageal cancer	0.000419	0.00312	CcSEcCtD
Brimonidine—Cough—Methotrexate—esophageal cancer	0.000413	0.00308	CcSEcCtD
Brimonidine—Arthralgia—Methotrexate—esophageal cancer	0.000403	0.00301	CcSEcCtD
Brimonidine—Chest pain—Methotrexate—esophageal cancer	0.000403	0.00301	CcSEcCtD
Brimonidine—Myalgia—Methotrexate—esophageal cancer	0.000403	0.00301	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000401	0.00299	CcSEcCtD
Brimonidine—Discomfort—Methotrexate—esophageal cancer	0.000398	0.00297	CcSEcCtD
Brimonidine—Infection—Methotrexate—esophageal cancer	0.000384	0.00286	CcSEcCtD
Brimonidine—Hypersensitivity—Capecitabine—esophageal cancer	0.000383	0.00285	CcSEcCtD
Brimonidine—Nervous system disorder—Methotrexate—esophageal cancer	0.000379	0.00283	CcSEcCtD
Brimonidine—Skin disorder—Methotrexate—esophageal cancer	0.000376	0.0028	CcSEcCtD
Brimonidine—Asthenia—Capecitabine—esophageal cancer	0.000373	0.00278	CcSEcCtD
Brimonidine—Pruritus—Capecitabine—esophageal cancer	0.000367	0.00274	CcSEcCtD
Brimonidine—Hypotension—Methotrexate—esophageal cancer	0.000361	0.00269	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000352	0.00263	CcSEcCtD
Brimonidine—Insomnia—Methotrexate—esophageal cancer	0.00035	0.00261	CcSEcCtD
Brimonidine—Paraesthesia—Methotrexate—esophageal cancer	0.000347	0.00259	CcSEcCtD
Brimonidine—Dyspnoea—Methotrexate—esophageal cancer	0.000345	0.00257	CcSEcCtD
Brimonidine—Somnolence—Methotrexate—esophageal cancer	0.000344	0.00256	CcSEcCtD
Brimonidine—Dizziness—Capecitabine—esophageal cancer	0.000343	0.00256	CcSEcCtD
Brimonidine—Dyspepsia—Methotrexate—esophageal cancer	0.00034	0.00254	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000334	0.00249	CcSEcCtD
Brimonidine—Fatigue—Methotrexate—esophageal cancer	0.000333	0.00249	CcSEcCtD
Brimonidine—Pain—Methotrexate—esophageal cancer	0.000331	0.00247	CcSEcCtD
Brimonidine—Rash—Capecitabine—esophageal cancer	0.000327	0.00244	CcSEcCtD
Brimonidine—Dermatitis—Capecitabine—esophageal cancer	0.000327	0.00244	CcSEcCtD
Brimonidine—Headache—Capecitabine—esophageal cancer	0.000325	0.00243	CcSEcCtD
Brimonidine—Nausea—Capecitabine—esophageal cancer	0.000308	0.0023	CcSEcCtD
Brimonidine—Hypersensitivity—Methotrexate—esophageal cancer	0.000285	0.00212	CcSEcCtD
Brimonidine—Asthenia—Methotrexate—esophageal cancer	0.000277	0.00207	CcSEcCtD
Brimonidine—Pruritus—Methotrexate—esophageal cancer	0.000274	0.00204	CcSEcCtD
Brimonidine—Dizziness—Methotrexate—esophageal cancer	0.000256	0.00191	CcSEcCtD
Brimonidine—Rash—Methotrexate—esophageal cancer	0.000244	0.00182	CcSEcCtD
Brimonidine—Dermatitis—Methotrexate—esophageal cancer	0.000244	0.00182	CcSEcCtD
Brimonidine—Headache—Methotrexate—esophageal cancer	0.000242	0.00181	CcSEcCtD
Brimonidine—Nausea—Methotrexate—esophageal cancer	0.00023	0.00171	CcSEcCtD
Brimonidine—ADRA2C—Hemostasis—ABL1—esophageal cancer	0.000146	0.00109	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PDE4D—esophageal cancer	0.000146	0.00109	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CXCL2—esophageal cancer	0.000144	0.00108	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—WWOX—esophageal cancer	0.000143	0.00107	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKAP13—esophageal cancer	0.000143	0.00107	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—SLC10A2—esophageal cancer	0.000142	0.00106	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CA1—esophageal cancer	0.000142	0.00106	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—GNG7—esophageal cancer	0.000139	0.00104	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—HMOX1—esophageal cancer	0.000137	0.00102	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FKBP1A—esophageal cancer	0.000136	0.00102	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CXCL2—esophageal cancer	0.000135	0.00101	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—ANXA1—esophageal cancer	0.000134	0.001	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—WWOX—esophageal cancer	0.000134	0.001	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KMT2D—esophageal cancer	0.000134	0.000996	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—WIF1—esophageal cancer	0.000133	0.000995	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ABCB1—esophageal cancer	0.000132	0.000983	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CXCL2—esophageal cancer	0.000131	0.000978	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PDE4D—esophageal cancer	0.000131	0.000975	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ADH1B—esophageal cancer	0.000131	0.000975	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—SST—esophageal cancer	0.000131	0.000974	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CA2—esophageal cancer	0.00013	0.000971	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKAP13—esophageal cancer	0.00013	0.000968	CbGpPWpGaD
Brimonidine—AOX1—Disease—HIF1A—esophageal cancer	0.000129	0.00096	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FKBP1A—esophageal cancer	0.000127	0.000951	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—GHRL—esophageal cancer	0.000127	0.000949	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—ANXA1—esophageal cancer	0.000125	0.000935	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—TYMP—esophageal cancer	0.000125	0.000931	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—WIF1—esophageal cancer	0.000125	0.000929	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—GNG7—esophageal cancer	0.000124	0.000928	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CSNK1A1—esophageal cancer	0.000123	0.000918	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCL2—esophageal cancer	0.000123	0.000914	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—SST—esophageal cancer	0.000122	0.00091	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—ANXA1—esophageal cancer	0.000122	0.000909	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP26A1—esophageal cancer	0.000121	0.000906	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PLCE1—esophageal cancer	0.000121	0.000903	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ADH7—esophageal cancer	0.000121	0.000903	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000119	0.000888	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—GHRL—esophageal cancer	0.000119	0.000887	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—ABL1—esophageal cancer	0.000119	0.000886	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PDE4D—esophageal cancer	0.000119	0.000886	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—SST—esophageal cancer	0.000119	0.000885	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ALOX15—esophageal cancer	0.000118	0.000883	CbGpPWpGaD
Brimonidine—AOX1—Disease—NOS2—esophageal cancer	0.000117	0.000873	CbGpPWpGaD
Brimonidine—AOX1—Disease—NOTCH1—esophageal cancer	0.000116	0.000865	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—GHRL—esophageal cancer	0.000116	0.000862	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PFN1—esophageal cancer	0.000115	0.000859	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CSNK1A1—esophageal cancer	0.000115	0.000858	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—ANXA1—esophageal cancer	0.000114	0.000849	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—GNG7—esophageal cancer	0.000113	0.000842	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—TPI1—esophageal cancer	0.000113	0.000842	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GSTO1—esophageal cancer	0.000113	0.000842	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—NOS2—esophageal cancer	0.000113	0.000842	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—SST—esophageal cancer	0.000111	0.000826	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCL2—esophageal cancer	0.00011	0.000817	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—WWOX—esophageal cancer	0.000109	0.000812	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ALDOB—esophageal cancer	0.000108	0.000807	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—GHRL—esophageal cancer	0.000108	0.000805	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PFN1—esophageal cancer	0.000108	0.000802	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ADH1B—esophageal cancer	0.000106	0.000792	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—NOS2—esophageal cancer	0.000105	0.000787	CbGpPWpGaD
Brimonidine—AOX1—Disease—CREBBP—esophageal cancer	0.000105	0.000784	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GAPDH—esophageal cancer	0.000104	0.000777	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FKBP1A—esophageal cancer	0.000104	0.000772	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ELMO1—esophageal cancer	0.000103	0.000771	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CRABP1—esophageal cancer	0.000103	0.00077	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000102	0.00076	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—TYMP—esophageal cancer	0.000101	0.000756	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—CREBBP—esophageal cancer	0.000101	0.000756	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—WIF1—esophageal cancer	0.000101	0.000755	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKAP13—esophageal cancer	0.000101	0.000754	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCL2—esophageal cancer	9.95e-05	0.000742	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—SST—esophageal cancer	9.91e-05	0.000739	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	9.91e-05	0.000739	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP26A1—esophageal cancer	9.87e-05	0.000736	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GNG7—esophageal cancer	9.82e-05	0.000733	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ELMO1—esophageal cancer	9.66e-05	0.000721	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—GHRL—esophageal cancer	9.66e-05	0.00072	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ALOX15—esophageal cancer	9.62e-05	0.000717	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—CREBBP—esophageal cancer	9.47e-05	0.000706	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKAP13—esophageal cancer	9.44e-05	0.000704	CbGpPWpGaD
Brimonidine—AOX1—Disease—NOS3—esophageal cancer	9.41e-05	0.000702	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CSNK1A1—esophageal cancer	9.34e-05	0.000697	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HIST1H2BM—esophageal cancer	9.33e-05	0.000696	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	9.26e-05	0.00069	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—ANXA1—esophageal cancer	9.25e-05	0.00069	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PDE4D—esophageal cancer	9.25e-05	0.00069	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ALDH2—esophageal cancer	9.21e-05	0.000687	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GSTO1—esophageal cancer	9.17e-05	0.000684	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—TPI1—esophageal cancer	9.17e-05	0.000684	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—NOS3—esophageal cancer	9.08e-05	0.000677	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—SST—esophageal cancer	9e-05	0.000671	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—CREBBP—esophageal cancer	8.8e-05	0.000657	CbGpPWpGaD
Brimonidine—AOX1—Disease—ERBB2—esophageal cancer	8.8e-05	0.000657	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GNG7—esophageal cancer	8.79e-05	0.000656	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ALDOB—esophageal cancer	8.79e-05	0.000656	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—GHRL—esophageal cancer	8.77e-05	0.000654	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GSTT1—esophageal cancer	8.76e-05	0.000653	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PFN1—esophageal cancer	8.74e-05	0.000652	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HIST1H2BM—esophageal cancer	8.71e-05	0.00065	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP2A6—esophageal cancer	8.66e-05	0.000646	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PDE4D—esophageal cancer	8.64e-05	0.000644	CbGpPWpGaD
Brimonidine—AOX1—Disease—PTGS2—esophageal cancer	8.61e-05	0.000642	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—NOS2—esophageal cancer	8.57e-05	0.000639	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—NOS3—esophageal cancer	8.48e-05	0.000632	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GAPDH—esophageal cancer	8.47e-05	0.000631	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CRABP1—esophageal cancer	8.39e-05	0.000626	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—XIAP—esophageal cancer	8.24e-05	0.000615	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GNG7—esophageal cancer	8.21e-05	0.000613	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ENO1—esophageal cancer	8.21e-05	0.000612	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTGS1—esophageal cancer	8.21e-05	0.000612	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PSME2—esophageal cancer	8.09e-05	0.000603	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PSME1—esophageal cancer	8.09e-05	0.000603	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GNG7—esophageal cancer	7.98e-05	0.000595	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—NOS3—esophageal cancer	7.88e-05	0.000588	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ELMO1—esophageal cancer	7.85e-05	0.000585	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CTNNA1—esophageal cancer	7.79e-05	0.000581	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCL2—esophageal cancer	7.75e-05	0.000578	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—XIAP—esophageal cancer	7.7e-05	0.000574	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—CREBBP—esophageal cancer	7.69e-05	0.000574	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKAP13—esophageal cancer	7.67e-05	0.000572	CbGpPWpGaD
Brimonidine—AOX1—Disease—CDKN1A—esophageal cancer	7.53e-05	0.000561	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	7.52e-05	0.000561	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ALDH2—esophageal cancer	7.48e-05	0.000558	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CTNNA1—esophageal cancer	7.28e-05	0.000543	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PSME2—esophageal cancer	7.24e-05	0.00054	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PSME1—esophageal cancer	7.24e-05	0.00054	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCL2—esophageal cancer	7.24e-05	0.00054	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PTGS2—esophageal cancer	7.21e-05	0.000538	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ANXA1—esophageal cancer	7.2e-05	0.000537	CbGpPWpGaD
Brimonidine—AOX1—Disease—EP300—esophageal cancer	7.16e-05	0.000534	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GSTT1—esophageal cancer	7.11e-05	0.00053	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HIST1H2BM—esophageal cancer	7.08e-05	0.000528	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP2A6—esophageal cancer	7.03e-05	0.000524	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDE4D—esophageal cancer	7.02e-05	0.000523	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SST—esophageal cancer	7.01e-05	0.000523	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP1B1—esophageal cancer	6.98e-05	0.00052	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—EP300—esophageal cancer	6.91e-05	0.000515	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—NOS3—esophageal cancer	6.89e-05	0.000514	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GHRL—esophageal cancer	6.83e-05	0.000509	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOTCH3—esophageal cancer	6.83e-05	0.000509	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PSME1—esophageal cancer	6.76e-05	0.000504	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PSME2—esophageal cancer	6.76e-05	0.000504	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ANXA1—esophageal cancer	6.73e-05	0.000502	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FBXW7—esophageal cancer	6.72e-05	0.000501	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GNG7—esophageal cancer	6.67e-05	0.000498	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ENO1—esophageal cancer	6.66e-05	0.000497	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTGS1—esophageal cancer	6.66e-05	0.000497	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PSME2—esophageal cancer	6.57e-05	0.00049	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PSME1—esophageal cancer	6.57e-05	0.00049	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CYP19A1—esophageal cancer	6.56e-05	0.000489	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SST—esophageal cancer	6.55e-05	0.000488	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—EP300—esophageal cancer	6.45e-05	0.000481	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GHRL—esophageal cancer	6.38e-05	0.000476	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOTCH3—esophageal cancer	6.38e-05	0.000476	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FBXW7—esophageal cancer	6.28e-05	0.000468	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—XIAP—esophageal cancer	6.25e-05	0.000466	CbGpPWpGaD
Brimonidine—AOX1—Disease—MYC—esophageal cancer	6.24e-05	0.000465	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOTCH2—esophageal cancer	6.12e-05	0.000457	CbGpPWpGaD
Brimonidine—AOX1—Disease—EGFR—esophageal cancer	6.1e-05	0.000455	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—EP300—esophageal cancer	6e-05	0.000447	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—HMOX1—esophageal cancer	5.99e-05	0.000446	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CTNNA1—esophageal cancer	5.91e-05	0.000441	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCL2—esophageal cancer	5.88e-05	0.000438	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ABCB1—esophageal cancer	5.75e-05	0.000428	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOTCH2—esophageal cancer	5.72e-05	0.000427	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP1B1—esophageal cancer	5.67e-05	0.000423	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PSME1—esophageal cancer	5.49e-05	0.00041	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PSME2—esophageal cancer	5.49e-05	0.00041	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ANXA1—esophageal cancer	5.47e-05	0.000408	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TGFBR2—esophageal cancer	5.43e-05	0.000405	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP19A1—esophageal cancer	5.33e-05	0.000397	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SST—esophageal cancer	5.32e-05	0.000397	CbGpPWpGaD
Brimonidine—AOX1—Disease—PIK3CA—esophageal cancer	5.3e-05	0.000395	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—EP300—esophageal cancer	5.24e-05	0.000391	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GHRL—esophageal cancer	5.18e-05	0.000386	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH3—esophageal cancer	5.18e-05	0.000386	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SMAD4—esophageal cancer	5.14e-05	0.000384	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—PIK3CA—esophageal cancer	5.11e-05	0.000381	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FBXW7—esophageal cancer	5.1e-05	0.00038	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TGFBR2—esophageal cancer	5.08e-05	0.000379	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TP53—esophageal cancer	4.94e-05	0.000369	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—HMOX1—esophageal cancer	4.86e-05	0.000363	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SMAD4—esophageal cancer	4.8e-05	0.000358	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—PIK3CA—esophageal cancer	4.77e-05	0.000356	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ABCB1—esophageal cancer	4.67e-05	0.000348	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH2—esophageal cancer	4.65e-05	0.000347	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TP53—esophageal cancer	4.62e-05	0.000344	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PIK3CA—esophageal cancer	4.44e-05	0.000331	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HIF1A—esophageal cancer	4.21e-05	0.000314	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	4.12e-05	0.000307	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KDR—esophageal cancer	4.02e-05	0.0003	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HIF1A—esophageal cancer	3.93e-05	0.000293	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	3.9e-05	0.000291	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	3.88e-05	0.000289	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CREBBP—esophageal cancer	3.84e-05	0.000286	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOTCH1—esophageal cancer	3.79e-05	0.000283	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KDR—esophageal cancer	3.76e-05	0.00028	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—esophageal cancer	3.75e-05	0.00028	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOTCH1—esophageal cancer	3.54e-05	0.000264	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—NOS3—esophageal cancer	3.44e-05	0.000256	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CREBBP—esophageal cancer	3.44e-05	0.000256	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—EGFR—esophageal cancer	3.38e-05	0.000252	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	3.23e-05	0.000241	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CREBBP—esophageal cancer	3.21e-05	0.000239	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	3.19e-05	0.000238	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—EGFR—esophageal cancer	3.16e-05	0.000235	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTGS2—esophageal cancer	3.14e-05	0.000235	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CREBBP—esophageal cancer	3.12e-05	0.000233	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	3.08e-05	0.00023	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KDR—esophageal cancer	3.05e-05	0.000228	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CA—esophageal cancer	3.02e-05	0.000225	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	2.93e-05	0.000219	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	2.88e-05	0.000215	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	2.88e-05	0.000215	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	2.87e-05	0.000214	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—NOS3—esophageal cancer	2.79e-05	0.000208	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	2.74e-05	0.000204	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	2.69e-05	0.000201	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—EP300—esophageal cancer	2.62e-05	0.000195	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	2.61e-05	0.000195	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	2.56e-05	0.000191	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTGS2—esophageal cancer	2.55e-05	0.00019	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	2.54e-05	0.00019	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	2.46e-05	0.000183	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.45e-05	0.000183	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	2.38e-05	0.000177	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EP300—esophageal cancer	2.34e-05	0.000175	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	2.34e-05	0.000174	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	2.3e-05	0.000171	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	2.22e-05	0.000166	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EP300—esophageal cancer	2.19e-05	0.000163	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	2.18e-05	0.000163	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—EP300—esophageal cancer	2.12e-05	0.000158	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—esophageal cancer	2.04e-05	0.000152	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	2e-05	0.000149	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CA—esophageal cancer	1.93e-05	0.000144	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	1.93e-05	0.000144	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—esophageal cancer	1.91e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	1.87e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	1.86e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EP300—esophageal cancer	1.78e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	1.73e-05	0.000129	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—esophageal cancer	1.68e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	1.62e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CA—esophageal cancer	1.57e-05	0.000117	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—esophageal cancer	1.56e-05	0.000117	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—esophageal cancer	1.55e-05	0.000115	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	1.51e-05	0.000113	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	1.31e-05	9.8e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—esophageal cancer	1.27e-05	9.48e-05	CbGpPWpGaD
